(Reuters) - The U.S. Food and Drug Administration has postponed a crucial meeting of an advisory committee to consider a cheap version of a top-selling drug for rheumatoid arthritis and Crohn's disease, which had been scheduled for March 17.
via Reuters: Health News Read More Here..
No comments:
Post a Comment